Pipeline report flags continued pressure The insurer's annual outlook, aimed at private plan sponsors, lists GLP-1 therapies among the leading themes of 2026 and warns that ongoing launches of newer, more expensive drugs are putting increased financial pressure on private drug plans [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
This shift was largely due to drugs laced with opioids, particularly the synthetic opioid, fentanyl
You want to support your immune system fuel levels during periods of high stress
Thats why we combined Preforpro prebiotic bacteriophage and postbiotic tributyrin to create a cutting-edge gut supplement that works with your gut ecosystem
A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis
The high cost of insulin continues to concern patients, providers and legislators alike, and pharma companies are attempting to slash prices